title: [Modulation effect of bis (alpha-furancarboxylato) oxovanadium (IV) on blood glucose in diabetic rats].
abstract: OBJECTIVE
  To study the hypoglycemic effect of bis (alpha-furancarboxylato) oxovanadium (IV) (VO-FA) in normal rats and streptozotocin (STZ)-diabetic rats.
  
  
  METHODS
  Rats were injected intraperitoneally STZ 50 mg.kg(-1) to induce diabetes. Blood glucose, glycohemoglobin, glycogen and serum insulin were observed after administering intragastrically VO-FA for four weeks.
  
  
  RESULTS
  After 2 weeks administration, VO-FA reduced the blood glucose in STZ-rats (P < 0. 01) dose-dependently, and up to 4 weeks the blood glucose was normalized (below 11.1 mmol.L(-1)) in some of STZ-rats, whereas did not decrease in normal rats. After administration of VO-FA at the dosage of 56.8 and 113.6 mg.kg(-1), the serum insulin levels were lowered in normal rats and STZ-rats, respectively. Moreover, VO-FA reduced glycohemoglobin, improved the glucose tolerance, and increased the liver glycogen and muscle glycogen contents in STZ-rats in a dose-dependent manner (P < 0. 05, P < 0. 01), but not in normal rats.
  
  
  CONCLUSIONS
  VO-FA could improve the glycometabolism in STZ-rats, but not in normal rats.
authors.affiliation: Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, Kunming 650031, China.
authors.forename: Li-Hui
authors.initials: LH
authors.lastname: Gao
authors.forename: Ming-Jin
authors.initials: MJ
authors.lastname: Xie
authors.forename: Ling
authors.initials: L
authors.lastname: Li
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Liu
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Li
authors.forename: Zhi-He
authors.initials: ZH
authors.lastname: Chen
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014639:Vanadium / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D009942:Organometallic Compounds; D014639:Vanadium; C512927:bis(alpha-furancarboxylato)oxovanadium(IV)